£50.00

It has never been this cheap. We have no record of a lower price.

£50 today · cheaper than every other day in the last 3 months

ÉDITIONS UNIVERSITAIRES EUROPÉENNES Traitement de l’hépatite virale C chronique: par les antiviraux à action directe au Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 37 days · 37 data points (no recent data)

Historical
Generating forecast…
£50.00 £47.50 £48.50 £49.50 £50.50 £51.50 £52.50 11 August 2026 20 August 2026 29 August 2026 07 September 2026 16 September 2026
View at Amazon ↗

Price data last checked 54 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 37 days • 1 price levels

Days at Price
37 days 0 9 19 28 37 £50 Days at Price

Price Analysis

Most common price: £50 (37 days, 100.0%)

Price range: £50 - £50

Price levels: 1 different prices over 37 days

Description

Les antiviraux à action directe ont révolutionné le traitement de l'hépatite C. Ces molécules sont disponibles au Burkina Faso depuis 2016. L'étude rapportée dans cet ouvrage avait pour objectif d'évaluer leur efficacité dans le traitement de l'hépatite virale C, dans un contexte de ressources limitées. Elle incluait les patients traités par des AAD au Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou entre le 1er mars 2016 et le 30 septembre 2019. Au total 76 patients ont été inclus, dont 20 (26,3%) avaient une fibrose sévère ou une cirrhose. Les patients étaient de génotype 2 (73,7%), 1 (21%), 4 (2,6%) et 5 (2,6%). Les protocoles thérapeutiques utilisés étaient le sofosbuvir-ribavirine, le sofosbuvir-velpatasvir ± ribavirine, le sofosbuvir-lédipasvir ± ribavirine et le sofosbuvir-daclatasvir ± ribavirine. L'efficacité globale du traitement était de 94,4%, avec un excellent profil de tolérance. Le protocole sofosbuvir-ribavirine majoritairement utilisé dans notre étude, n'est actuellement plus recommandé. Cette étude aborde les difficultés d'accès au traitement en Afrique sub-saharienne et le challenge économique que représenteraient le dépistage universel.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
30 June 2020
Listed Since
17 July 2020

Barcode

No barcode data available

Similar Products You Might Like

Hepatitis Prevention and Treatment (Milestones in Drug Therapy)
79% match

Hepatitis Prevention and Treatment (Milestones in Drug Therapy)

Birkhauser

£129.04 22 Oct 2026
Machine Learning for Predicting Hepatitis C Virus Therapy Outcomes: HCV in Egypt
79% match

Machine Learning for Predicting Hepatitis C Virus Therapy Outcomes: HCV in Egypt

LAP Lambert Academic Publishing

£42.00 14 Sep 2026
Therapeutic Potentials of Tenofovir Alafenamide in Hepatitis B
79% match

Therapeutic Potentials of Tenofovir Alafenamide in Hepatitis B

Elsevier

£137.99 24 Oct 2026
Hepatitis C Virus: The Next Epidemic, An issue of Gastroenterology Clinics of North America (Volume 44-4) (The Clinics: Internal Medicine, Volume 44-4)
78% match

Hepatitis C Virus: The Next Epidemic, An issue of Gastroenterology Clinics of North America (Volume 44-4) (The Clinics: Internal Medicine, Volume 44-4)

Elsevier

£55.00 09 Sep 2026
RIBAVIRIN: Biochemistry, Clinical Applications & Potential Side Effects (Pharmacology-research, Safety Testing and Regulation)
78% match

RIBAVIRIN: Biochemistry, Clinical Applications & Potential Side Effects (Pharmacology-research, Safety Testing and Regulation)

£58.24 14 Sep 2026
Arbidol: an antiviral against globally prevalent viruses: A promising antiviral strategy
78% match

Arbidol: an antiviral against globally prevalent viruses: A promising antiviral strategy

VDM Verlag

£35.91 24 Oct 2026
Hepatitis Prevention and Treatment (Milestones in Drug Therapy)
77% match

Hepatitis Prevention and Treatment (Milestones in Drug Therapy)

Birkhauser

£108.70 22 Oct 2026
Hepatitis B Virus and Liver Disease
76% match

Hepatitis B Virus and Liver Disease

Springer

£89.28 26 Oct 2026
Dépistage de l'hépatite C: Un enjeu de santé publique (Omn.Pres.Franc.)
76% match

Dépistage de l'hépatite C: Un enjeu de santé publique (Omn.Pres.Franc.)

OmniScriptum

£76.00 15 Sep 2026
Hepatitis C Virus and Liver Transplantation
76% match

Hepatitis C Virus and Liver Transplantation

Springer

£73.14 24 Oct 2026
T reg cells in chronic HCV infection and Mixedcryoglobulinemia: An immunological study of chronic Hepatitis C Virus infection in Egypt
76% match

T reg cells in chronic HCV infection and Mixedcryoglobulinemia: An immunological study of chronic Hepatitis C Virus infection in Egypt

LAP Lambert Academic Publishing

£60.00 14 Sep 2026
The Hepatitis B and Delta Viruses (Cold Spring Harbor Perspectives in Medicine)
75% match

The Hepatitis B and Delta Viruses (Cold Spring Harbor Perspectives in Medicine)

Cold Spring Harbor Laboratory Press

£74.90 13 Oct 2026
Tizoxanide Inhibits HCV Replication Through NS5A Hyperphosporylation
75% match

Tizoxanide Inhibits HCV Replication Through NS5A Hyperphosporylation

VDM Verlag

£75.15 15 Sep 2026
HIV and Liver Disease
75% match

HIV and Liver Disease

Springer

£80.67 22 Oct 2026
Genetic Signatures for Progression and Response of Hepatitis C: Apoptosis and Hepatitis C: Genetic and Hormonal Predictors
75% match

Genetic Signatures for Progression and Response of Hepatitis C: Apoptosis and Hepatitis C: Genetic and Hormonal Predictors

LAP Lambert Academic Publishing

£67.00 15 Sep 2026
Chronic Hepatitis B And C: Basic Science To Clinical Applications
75% match

Chronic Hepatitis B And C: Basic Science To Clinical Applications

World Scientific Publishing Company

£65.09 15 Sep 2026
Treatment strategies of HCV patients in different medical conditions
74% match

Treatment strategies of HCV patients in different medical conditions

LAP Lambert Academic Publishing

£68.00 26 Aug 2026
Hepadnaviruses: Molecular Biology and Pathogenesis: 168 (Current Topics in Microbiology and Immunology, 168)
74% match

Hepadnaviruses: Molecular Biology and Pathogenesis: 168 (Current Topics in Microbiology and Immunology, 168)

Springer

£75.41 24 Oct 2026
Mechanisms involved in resistance to interferon alpha therapy in HCV
74% match

Mechanisms involved in resistance to interferon alpha therapy in HCV

LAP Lambert Academic Publishing

£74.00 04 Nov 2026
Hepatitis B Virus, An Issue of Clinics in Liver Disease (Volume 23-2) (The Clinics: Internal Medicine, Volume 23-2)
74% match

Hepatitis B Virus, An Issue of Clinics in Liver Disease (Volume 23-2) (The Clinics: Internal Medicine, Volume 23-2)

Elsevier

£69.11 13 Sep 2026
Hepatitis Viruses
74% match

Hepatitis Viruses

Springer

£52.07 13 Sep 2026
Viral Hepatitis in Children: Unique Features and Opportunities (Clinical Gastroenterology)
73% match

Viral Hepatitis in Children: Unique Features and Opportunities (Clinical Gastroenterology)

Humana

£103.48 03 Nov 2026
Hepatoprotective Potential of Euphorbia hirta: A Challenge against Antitubercular Drug induced Hepatotoxicity
73% match

Hepatoprotective Potential of Euphorbia hirta: A Challenge against Antitubercular Drug induced Hepatotoxicity

LAP Lambert Academic Publishing

£66.00 15 Sep 2026
Viral Hepatitis: Diagnosis, Therapy, and Prevention
73% match

Viral Hepatitis: Diagnosis, Therapy, and Prevention

Humana

£59.94 14 Sep 2026